Resources
Bloomberg Law Publish Date: November 14, 2022 Read the Full Article >> More than half of women ages 15 to 49 who use a common arthritis drug risk losing access under restrictive state abortion laws, according to a new study based on nationwide health-care data. The analysis, published Saturday in the Arthritis & Rheumatology Journal, found[…]
AdvaMed Publish Date: November 3, 2022 Read the Full Article>> Challenges of AI in MedTech In the medical device space, powerful insights from real-world data can seem ‘just out of reach’. Capturing patient characteristics and outcomes, at scale and with consistency over time, is challenging outside of clinical trials. Personalization – bridging the gap between[…]
Listen to OM1’s podcast episode on the Medical Affairs Professional Society (MAPS) “Elevate” podcast series. Dr. Carl Marci is discussing the use of Real-World Data and Real-World Evidence to understand and possibly intercede in treatment-resistant depression and why it is especially difficult to develop treatments against resistant depression using the traditional structure of R&D-led clinical[…]
Tue, Oct 18, 2022 11:00 AM – 12:00 PM EDT Presenter: Joseph Zabinski, Senior Director, AI & Precision Medicine, OM1 Register >> As population health moves towards personalized, precision medicine, optimizing treatment options and reducing ineffective care will be critical to plans’ success and differentiation in highly competitive environments. Real-world evidence drawn from deep datasets[…]
Available for licensing and analytics, these datasets enable faster access to research-grade IBD condition data, including longitudinal outcomes BOSTON, Sept. 14, 2022 /PRNewswire/ — OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the launch of its PremiOM™ Ulcerative Colitis (UC) and Crohn’s Disease (CD) datasets, providing[…]
